INJECTION SCHEMES Russian patent published in 2022 - IPC A61K38/04 A61K38/12 A61P27/02 

FIELD: medicine; ophthalmology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to ophthalmology; it is intended for the treatment of a complement-mediated ocular disorder, namely age-related macular dystrophy (hereinafter – AMD). A method for the treatment of a complement-mediated ocular disorder includes the injection to a subject who needs it of a long-acting compstatin analog (hereinafter – LACA). The specified LACA contains a clearance-reducing fragment connected to two compstatin analog fragments, wherein each compstatin analog fragment contains cyclic peptide with an amino acid sequence represented in SEQ ID NO: 28, elongated with lysin residue at C-end, wherein lysin residue is separated from a cyclic part with 8-amino-3,6-dioxaoctanoic acid (AEEAc)-spacer. The specified clearance-reducing fragment contains polymer, wherein each polymer end is bound to an amino group of a side chain of lysin residue of one of compstatin analog fragments via carbamate, and polymer is PEG with an average molecular weight of 40 kDa. The specified complement-mediated ocular disorder is AMD. The specified treatment includes intravitreal injection once a month or once every two months of the specified LACA to the eye of the specified subject in the amount from 10 mg to 20 mg. In other embodiments, the use of LACA in the treatment of AMD, and the use of a single dosed form of LACA in the treatment of AMD in a subject who needs it are presented.

EFFECT: use of the group of inventions provides for a new therapeutic mode for the effective treatment of a complement-mediated ocular disorder, such as AMD.

25 cl, 12 dwg, 12 tbl, 28 ex